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ABSTRACT
Objective: Progression-free survival (PFS) is
frequently used as an efficacy end point in oncology
clinical trials. However, there is limited evidence to
support a positive association between improvement in
PFS and improvement in health-related quality of life
(HRQoL). The association between PFS and HRQoL
was evaluated in two randomised trials.
Materials and methods: Data from two randomised
controlled trials in patients with non-small cell lung
cancer (NSCLC; LUX-Lung 1 and LUX-Lung 3) were
used to investigate HRQoL in patients to determine
whether tumour progression is accompanied by
worsening HRQoL. HRQoL was assessed using the
cancer-specific European Organization for Research
and Treatment of Cancer (EORTC) core questionnaire
QLQ-C30, the EuroQol EQ-5D overall utility and
EuroQol EQ visual analogue scale. In both studies,
progression was evaluated by independent review
using RECIST criteria (primary end point) and also by
investigator assessment. The relationship between
tumour progression and HRQoL was evaluated using
analysis of covariance and a longitudinal model.
Results: Compliance with HRQoL questionnaire
completion was high. In both studies, patients with
progression consistently experienced numerically
poorer HRQoL at the time of progression than patients
without progression. Differences in mean scores were
statistically significant (p<0.05) between patients with
and without progression at week 4 in all analyses in
LUX-Lung 1 and at multiple time points in LUX-Lung
3. Results from the longitudinal analysis showed that
progression (by independent review and investigator
assessment) appears to have consistent negative
impact on all three HRQoL measures (all p<0.0001).
Conclusions: Tumour progression in patients with
NSCLC was associated with statistically significant
worsening in HRQoL. These findings confirm the value
of PFS as a patient-relevant end point.
INTRODUCTION
Use of progression-free survival (PFS) as a
primary end point in oncology has increased
recently, as has its use as a secondary end
point.1 Using PFS, as opposed to overall sur-
vival (OS), has several advantages for clinical
trial conduct; trials that use PFS as a primary
end point can be conducted more quickly
and with fewer patients than trials using OS.1
This also beneﬁts patients as it allows earlier
access to new treatments as trial results are
available sooner when PFS is used as an end
point. PFS also directly measures the effect
of the investigational treatment and, unlike
OS, is insensitive to bias from subsequent
treatment(s) (ie, treatment received after
disease progression has been determined).2
This issue of bias in interpretation of OS
data is also compounded by the fact that use
of subsequent therapies generally differs
between treatment arms.2
Despite the advantages of PFS, there are
several limitations to consider. There are no
standard regulatory criteria for deﬁning pro-
gression in clinical trials2 and progression
can be difﬁcult to assess and subject to meas-
urement error and bias, especially if assessors
are not blinded to treatment.2 PFS is also
inﬂuenced by frequency of assessment,
unlike OS.3 Even though an improvement in
Strengths and limitations of this study
▪ A strength of our analyses is that they address
methodological limitations of previous studies
investigating this association and use data from
two different non-small cell lung cancer studies.
In addition, HRQoL was measured using vali-
dated assessment tools
▪ Limitations relate to the handling of missing
data, inherent in this type of analysis
▪ Limited data on the health states of patients with
progression was available; this is an additional
limitation.
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PFS is considered an indication of disease control and
stabilisation,4 there is still debate as to whether an
improvement in PFS is beneﬁcial for patients.5 As such,
it is important that PFS beneﬁts seen in clinical trials are
accompanied by better symptom control, fewer
treatment-related adverse events and better
health-related quality of life (HRQoL).1 4
While randomised controlled trials (RCTs) frequently
assess HRQoL as well as PFS, the design of such trials
only allows indirect inferences regarding a relationship
between PFS and HRQoL in situations wherein both are
inﬂuenced by treatment. For this reason, some health
technology assessment agencies6 do not consider PFS a
patient-relevant outcome measurement and usually
discard the information on this end point in their eva-
luations, particularly in indications and for investiga-
tional compounds where PFS may not be a
well-established surrogate for OS.
Thus, there is a need to establish the relationship
between changes in PFS and HRQoL. While many clin-
ical trials include HRQoL assessments as trial outcomes,
a major limitation in evaluating this relationship is that
HRQoL assessments are often only administered until
disease progression based on imaging results (which
may precede symptomatic progression) to avoid the con-
founding effects of subsequent therapies1 4 and to ease
administrative burden. A direct comparison of HRQoL
in patients who are considered progression-free with
those patients who experience tumour growth is often
limited.
Several investigators have assessed the relationship
between HRQoL and tumour response in patients with
breast, colorectal and renal cell cancer,7–10 and suggest
that patients who remain on treatment and who experi-
ence delayed progression have a stable HRQoL or
experience a less rapid decline in HRQoL than patients
whose tumours are progressing. To the best of our
knowledge, no data have been reported in non-small
cell lung cancer (NSCLC).
Two RCTs investigated the role of afatinib, an irreversible
ErbB Family Blocker, in NSCLC and included assessment
of patient-reported symptoms and HRQoL in addition to
tumour progression: LUX-Lung 1 (NCT00656136)11 12
and LUX-Lung 3 (NCT00949650).13 14 The analyses
reported here use data collected in these trials to investi-
gate HRQoL in patients before and after progression, and
to explore the relationship between tumour progression
and HRQoL. Two different statistical analysis methods were
used in order to assess the strength of the ﬁndings.
PATIENTS AND METHODS
Study design
This analysis used data from two RCTs.12 14 Key details
of the methodology and ﬁndings of these trials are sum-
marised in table 1.
Health-related quality of life assessment
HRQoL was assessed using the self-administered cancer-
speciﬁc European Organization for Research and
Treatment of Cancer (EORTC) multidimensional core
questionnaire QLQ-C30.15 QLQ-C30 comprises of 30
questions of multi-item and single-item measures.
Individual items are scored on a four-point scale, while
Global health status (question 29) and quality of life
(QoL, question 30) are scored on a seven-point scale.
Table 1 Summary of trial design and results of LUX-Lung 111 12 and LUX-Lung 313 14
LUX-Lung 1 (N=585) LUX-Lung 3 (N=345)
Inclusion criteria Stage IIIB (with pleural effusion) or stage IV
adenocarcinoma according to the TNM
classification system by the UICC 6th edition;
ECOG PS 0–2; patients were not screened for
EGFR mutation status
Patients with stage IIIB/IV lung adenocarcinoma
(AJCC Cancer Staging Manual 6th edition);
EGFR mutation positive disease (Therascreen
EGFR 29; Qiagen, Manchester, UK); ECOG PS
0–1
Previous treatment One or two lines of cytotoxic chemotherapy (one
of which was platinum-based) and progressive
disease following at least 12 weeks of treatment
with erlotinib or gefitinib
Treatment-naïve for advanced NSCLC
Study treatments 2:1 randomisation to 50 mg afatinib per day plus
best supportive care (n=390) or placebo plus
best supportive care (n=195)
2:1 randomisation to 40 mg afatinib per day
(n=230) or up to six cycles of cisplatin/
pemetrexed chemotherapy at standard dose
(n=115)
Primary endpoint OS (from date of randomisation to death) PFS (as determined by independent blinded
review)
Secondary endpoints Tumour response, PFS, HRQoL, adverse events Tumour response, OS, HRQoL, adverse events
PFS (afatinib vs
control) by
independent review
3.3 vs 1.1 months, HR=0.38, 95% CI 0.31 to
0.48; p<0.0001
11.1 vs 6.9 months, HR=0.58; 95% CI 0.43 to
0.78; p=0.001
AJCC, American Joint Committee on Cancer; ECOG PS, Eastern Cooperative Oncology Group Performance Status; EGFR, epidermal growth
factor receptor; HRQoL, health-related quality of life; NSCLC, non-small cell lung cancer; OS, overall survival; PFS, progression-free survival;
UICC, International Union Against Cancer.
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For the purpose of this analysis, the QLQ-C30 Global
health status/QoL (composite of QLQ-C30 questions 29
and 30) score was used to evaluate patients’ overall self-
reported HRQoL. The EuroQol disease-generic ques-
tionnaire, comprising the EQ-5D overall utility and
EQ-visual analogue scale (VAS),16 was used to assess
health status. The EQ-5D measures ﬁve dimensions of
health (mobility, self-care, usual activities, pain/discom-
fort and anxiety/depression). Utility scores range from 0
to 1 and were calculated from the ﬁve EQ-5D item
scores using the UK valuation algorithm.17 The EQ VAS
records the patient’s self-rated health status on a vertical
graduated (0–100) VAS.
In LUX-Lung 1, HRQoL questionnaires were sched-
uled at randomisation, two weekly during the ﬁrst
2 months of treatment and then every 4 weeks. In
LUX-Lung 3, HRQoL was assessed at randomisation and
every 21 days. For chemotherapy patients, this was on
day 1 of each cycle and was delayed if the chemotherapy
was delayed. In both studies, HRQoL was also assessed at
the end of treatment following treatment discontinu-
ation due to progression or other reasons and during at
least one follow-up visit.
The protocol for both studies required that patients
completed HRQoL questionnaires in the clinic using an
electronic portable data capture tool before they were
provided with any test results by their treating physicians
or any other health professional.
Assessment of tumour progression
Tumour assessments were performed by CT or MRI. In
LUX-Lung 1, tumour assessments were undertaken at
baseline and every 4 weeks until week 12, and then every
8 weeks until disease progression by independent review.
In LUX-Lung 3, tumour assessments were undertaken at
baseline and every 6 weeks for the ﬁrst 48 weeks and then
every 12 weeks thereafter until disease progression by
independent review or start of new anticancer therapy.
RECIST criteria were used for independent review, which
was conducted by a central imaging group that included
radiologist and oncologist reviewers blinded to treatment
assignments; investigators also assessed tumour progres-
sion based on radiological and clinical assessment in
both studies. In LUX-Lung 3, the primary end point was
based on independent review. Independent review is
regarded as the most conservative approach and is recom-
mended in RECIST guidelines.18 19
Statistical analyses
The statistical methods used in this analysis were prespe-
ciﬁed. For the main analyses, randomised treatment
groups were combined in order to increase the numbers
of patients available. Additional subgroup analyses were
conducted to assess consistency of results between
groups. To be included in analysis, patients had to have
completed a baseline assessment and at least one meas-
urement at the time of tumour progression or follow-up
assessment. A HRQoL assessment was considered valid
for inclusion in the statistical analysis if it occurred
within ±7 days of the date of tumour assessment. In the
event there was more than one HRQoL assessment, the
one nearest the actual tumour assessment date was used.
For patients who progressed, only the ﬁrst HRQoL
assessment was used; after that they were censored for
future time points. In the longitudinal analysis, all
HRQoL assessments at, or after progression, were used
but were censored at the start of any new anticancer
therapy. Assessments that were carried out after the start
of other subsequent cancer treatment following progres-
sion were excluded. All analyses were conducted using
data from independent review and investigator assess-
ment of tumour progression. Statistical programming
was carried out using S-Plus.
Analysis of covariance
The hypothesis for this analysis was that patients with and
without progression at any time would have different
average levels of QoL. At each assessment time (weeks 4,
8 and 12 in LUX-Lung 1 and weeks 6, 12, 18, 24, 30 and
36 in LUX-Lung 3), patients who were classiﬁed as pro-
gressors (having been ‘not progressed’ at the previous
assessment) were compared with patients who were
assessed as ‘non-progressors’ (between-patient analysis).
These time points were chosen for analysis based on the
availability of sufﬁcient data. Patients who had died since
the previous assessment were excluded from the analyses.
At each assessment time and for each HRQoL measure
(EORTC Global Health/QoL, EQ-5D UK Utility and EQ
VAS) change from baseline in HRQoL score between pro-
gressors and non-progressors was compared using an ana-
lysis of covariance (ANCOVA) model that included
covariates for baseline HRQoL score, progression,
Eastern Cooperative Oncology Group Performance
Status (ECOG PS; 0 vs ≥1), gender and randomised treat-
ment. Adjusted mean changes from baseline in HRQoL
measures over time for progressors and non-progressors
are presented graphically.
Consistency in the effects of progression was examined
by expanding the model to include interaction terms
between progression/non-progression and baseline
HRQoL, ECOG PS, gender and randomised treatment.
Longitudinal analysis
The effects of progression on HRQoL over time were
investigated using a longitudinal mixed-effects growth
curve model,20 21 which allows for within-patient assess-
ment of change in HRQoL at or after progression. The
model allowed the slope of the growth curve to change at
predetermined times since randomisation (weeks 2, 4, 8
and 12 for LUX-Lung 1 and weeks 3, 6, 12, 18 for
LUX-Lung 3, based on availability of sufﬁcient data). A
cut-off was applied to HRQoL data in each study such
that assessments were excluded when fewer than approxi-
mately 20–30% patients remained. Each model included
the two random effects of intercept and slope (the week
variable). The model included terms for week, covariates
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Figure 1 Flow chart of patients with disease progression by independent review and investigator assessment in LUX-Lung 1
(A) and LUX-Lung 3 (B). (QoL, quality of life). n, number of patients with progression by independent review/ investigator
assessment. Patients who are censored for progression before Week 4 (LUX-Lung 1) or Week 6 (LUX-Lung 3) may not have a
post-baseline HRQoL assessment; this explains the difference in the number of patients at Week 0 by each assessment method.
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related to progression status (either independent or
investigator assessment) as well as baseline covariates that
were used to stratify the randomisation scheme. Change
in HRQoL from baseline was modelled and there was no
term for randomised treatment.
Model diagnostics
For the ANCOVA as well as the longitudinal models,
several model diagnostics were carried out to determine
whether assumptions underlying the statistical models
were valid. Normality plots of residuals and random
effects, and plots of residuals against ﬁtted values were
carried out.
RESULTS
Patient population and compliance with patient-reported
assessments
Patient demographics and clinical characteristics were
similar between treatment arms in both trials. The
numbers of patients with progression by independent
review and investigator assessment at each study time
point are shown in ﬁgure 1. The difference in patient
numbers between independent review and investigator
assessment results from differences in censoring, death
of patients prior to the ﬁrst assessment, or differences in
assessment of progression between independent review
and investigator assessment.
Figure 2 Progression effect and adjusted mean change from baseline for Global health status/QoL, EQ-5D utility and EQ VAS
scores, by progression status in LUX-Lung 1 and LUX-Lung 3, independent review (QoL, quality of life; VAS, visual analogue
scale). Progression effect: *p<0.01, **p<0.05. Arrows indicate the direction of the mean change from baseline for Global health
status/QoL, EQ-5D utility and VAS scores in patients with and without progression at each assessment week.
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Baseline HRQoL questionnaires were completed by
94% of patients in LUX-Lung 1 and 97% of patients in
LUX-Lung 3.12 13 In both studies, compliance with ques-
tionnaire completion remained high (92–99%) at or
after progression, in both treatment groups. The mean
number of assessments at or after progression in patients
with at least one baseline assessment was 2.5 by inde-
pendent review and 1.4 by investigator assessment.
Results of ANCOVA
The progression effects (PEs) over the treatment period
in LUX-Lung 1 (12 weeks) and LUX-Lung 3 (36 weeks),
in terms of adjusted mean changes from baseline in
EORTC Global Health/QoL, EQ-5D UK Utility and EQ
VAS scores in patients with and without progression for
independent review, are shown in ﬁgure 2.
In LUX-Lung 1, patients with progression by inde-
pendent review consistently experienced numerically
poorer HRQoL at the time of progression than patients
without progression over the ﬁrst 12 weeks of treatment.
Mean scores differed signiﬁcantly between patients with
and without progression at week 4 for Global Health/
QoL (PE: −8.5), EQ-5D UK Utility (PE: −0.1) and EQ
VAS scores (PE: −7.3; all p<0.05). Differences in mean
change from baseline in VAS scores were also statistically
signiﬁcant (p<0.05) between patients who experienced
progression by independent review and those who did
not at week 8 (PE: −5.4). Results were similar for investi-
gator assessment of progression (see online supplemen-
tary ﬁgure 1).
In LUX-Lung 3, patients with progression by inde-
pendent review consistently experienced poorer HRQoL
progression than patients without progression.
Differences in mean change from baseline in EORTC
Global Health/QoL, EQ-5D UK Utility and EQ VAS
scores were statistically signiﬁcant between patients who
experienced progression and those who did not at mul-
tiple time points in all assessments (ﬁgure 2). Results
were similar for investigator assessment of progression
(see online supplementary ﬁgure 1).
Interaction tests investigating the PE with each of base-
line HRQoL and randomised treatment as well as with
gender and ECOG score in LUX-Lung 1, and EGFR
status and race in LUX-Lung 3 did not show any consist-
ent trend. This indicates that these factors do not have a
signiﬁcant impact on the analyses and therefore sup-
ports the conclusion that the effects of progression on
HRQoL that were identiﬁed by the ANCOVA models are
consistent throughout the patient population.
Results of the longitudinal analysis
Estimates of the effects of progression on HRQoL from
mixed-effects longitudinal models for LUX-Lung 1 and
LUX-Lung 3 are shown in table 2. In both trials, progres-
sion by independent review as well as investigator assess-
ment appeared to have consistent negative impact on all
three HRQoL measures, as indicated by the negative
coefﬁcients for progression.
Estimates of the effects of progression in each treat-
ment group separately, obtained from mixed-effects lon-
gitudinal models for LUX-Lung 1 and LUX-Lung 3,
showed no signiﬁcant differences between treatment
groups in either study (table 3). In all analyses, PEs were
consistently numerically higher when evaluated by inves-
tigator assessment than when evaluated by independent
review.
Model diagnostics
Diagnostic tests conﬁrmed that statistical methods were
appropriate for the data in the two studies.
DISCUSSION
Results from the two analyses reported here suggest that
tumour progression in patients with NSCLC is associated
with statistically signiﬁcant worsening in HRQoL, as mea-
sured using the EORTC QLQ-C30 Global Health/QoL
measure and EQ-5D UK Utility and VAS scores. These
ﬁndings are in agreement with previous studies in
patients with breast, colorectal and renal cell cancer7–10;
Table 2 Estimates of the effects of disease progression on HRQoL from mixed-effects longitudinal models for LUX-Lung 1
and LUX-Lung 3
HRQoL measure
Independent review Investigator assessment
Progression effect (95% CI) p Value Progression effect (95% CI) p Value
LUX-Lung 1
EORTC Global Health/QoL −4.24 (−6.09 to −2.40) <0.0001 −4.65 (−6.44 to −2.87) <0.0001
EQ-5D UK Utility −0.056 (−0.083 to −0.028) <0.0001 −0.065 (−0.092 to −0.039) <0.0001
EQ VAS −3.76 (−5.19 to −2.32) <0.0001 −3.83 (−5.21 to −2.44) <0.0001
LUX-Lung 3
EORTC Global Health/QoL −4.56 (−6.09 to −3.03) <0.0001 −5.62 (−7.27 to −3.96) <0.0001
EQ-5D UK Utility −0.061 (−0.082 to −0.041) <0.0001 −0.076 (−0.099 to −0.054) <0.0001
EQ VAS −3.62 (−4.79 to −2.45) <0.0001 −4.29 (−5.54 to −3.03) <0.0001
A negative value indicates a deterioration in HRQoL associated with progression.
CI, confidence interval; EORTC, European Organization for Research and Treatment of Cancer; VAS, Visual Analogue Scale; HRQoL,
health-related quality of life.
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however, to our knowledge, this is the ﬁrst study to show
an association between tumour progression and HRQoL
in patients with NSCLC.
Previous studies claiming an association between
HRQoL and disease progression have been criticised for
failing to apply quality assessment criteria developed to
avoid potential bias when evaluating this type of associ-
ation.4 Speciﬁcally, failure of analyses to censor patients
at the time of progression, inadequate adjustment for
confounding factors where necessary, inadequate
description of whether participants were aware of their
PFS status leading to potential performance bias and
failure to deﬁne an a priori hypothesis regarding the
relationship between PFS and HRQoL.4 In the analysis
reported here, HRQoL assessments up to and beyond
the time of PFS were included, confounding factors
(baseline covariates) were included in the ANCOVA and
analysis objectives and methods were clearly deﬁned. In
order to avoid potential performance bias, it was manda-
tory that patients completed HRQoL questionnaires
before receiving test results, although it is possible that
deviations from this may have occurred in practice.
Our results are strengthened by the use of validated
assessment tools for the evaluation of HRQoL and the
use of two separate analyses methods, which showed
consistent ﬁndings in two trials. The longitudinal model
analyses have several additional strengths over the
ANCOVA, and allow for within-patient comparison of
HRQoL and progression states, whereas ANCOVA only
considers between-patient comparisons. The longitu-
dinal model analyses use all available data and take
appropriate account of serial correlation within a
patient, resulting in more precise estimates of PE than
those from ANCOVA.20 In both trials, the HRQoL assess-
ments were comprehensive, providing a strong basis for
evaluating the relationship between HRQoL and disease
progression. Differences in the ﬁndings of the ANCOVA
results between LUX-Lung 1 and LUX-Lung 3 may
reﬂect the fact that clinically meaningful changes in
HRQoL may be harder to achieve in heavily pretreated
patients such as those included in LUX-Lung 1.
While the ﬁndings reported here indicate that disease
progression is accompanied by a statistically signiﬁcant
worsening of HRQoL, it should also be considered
whether the results represent a clinically meaningful
change in HRQoL. There is continued debate as to what
constitutes a meaningful change in oncology HRQoL
scores, with data suggesting that patients are more
responsive to improvement than decline,22 and that the
thresholds for clinically signiﬁcant improvement and
decline are not always uniform.23 While a 10-point
change in an individual patient’s EORTC QLQ-C30 item
or domain is an accepted threshold for clinically mean-
ingful improvement,24 different thresholds have been
proposed for intergroup changes for individual
QLQ-C30 QOL scales.25 For the QLQ-C30 Global health
status/QoL scale, a mean difference of 0–4 points repre-
sents a trivial effect, 4–10 point difference represents a
small but clinically important effect and a 10–15 differ-
ence represents a moderate effect.25 These thresholds
for QLQ-C30 Global health status/QoL imply that most
of the ﬁndings reported here are clinically meaningful.
For the EQ-5D UK Utility and EQ VAS scores, changes
of 0.06–0.11 and 7–12 points, respectively, have been
suggested to represent a minimally important differ-
ence,26 27 although there is no established consensus on
how best to determine the minimally important differ-
ence in HRQoL measures.26 Using these values as a
guide, some of the changes observed in our study
should be considered clinically meaningful.
Limitations should be considered. As more HRQoL
assessments were conducted up to the time of progres-
sion, and fewer at follow-up visit(s) following progres-
sion, limited data were available on the health state of
patients with progression; this is a common limitation of
this type of analysis.4 Further evaluation of HRQoL in
Table 3 Effects of disease progression from mixed-effects longitudinal models for LUX-Lung 1 and LUX-Lung 3 by
randomised treatment
HRQoL measure
Independent review Investigator assessment
Effect of progression
p Value for
difference
between
treatments Effect of progression
p Value for
difference
between
treatments
LUX-Lung 1 Afatinib Best supportive care Afatinib Best supportive care
EORTC Global Health/QoL −3.61 −5.96 0.27 −4.83 −4.27 0.78
EQ-5D UK Utility −0.060 −0.046 0.66 −0.081 −0.033 0.10
EQ VAS −3.63 −4.11 0.77 −4.42 −2.55 0.22
LUX-Lung 3 Afatinib Cisplatin/pemetrexed Afatinib Cisplatin/pemetrexed
EORTC Global Health/QoL −4.65 −4.34 0.85 −5.82 −5.15 0.72
EQ-5D UK Utility −0.068 −0.046 0.34 −0.083 −0.062 0.39
EQ VAS −4.00 −2.74 0.33 −4.39 −4.05 0.80
A negative value indicates a deterioration in HRQoL associated with progression.
CI, confidence interval; EORTC, European Organization for Research and Treatment of Cancer; HRQoL, health-related quality of life; VAS,
Visual Analogue Scale.
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these patients may have revealed more pronounced dif-
ferences in HRQoL between patients with and without
progression. Of the two trials, LUX-Lung 3 had more
HRQoL data after progression than LUX-Lung 1, indi-
cating that the results from analysis of LUX-Lung 3 data
are potentially more robust.
Accounting for, and minimising the impact of missing
data (which are often not missing at random as assumed
here) is an important factor in analyses such as ours.20 Full
details of compliance with HRQoL questionnaires have
been reported previously in the original reports of
HRQoL ﬁndings from LUX-Lung 1 11 and LUX-Lung 3.13
In both trials, compliance with questionnaire completion
was high over the duration of treatment in each trial
(LUX-Lung 1, 65–100%; LUX-Lung 3, >90%), which
helps to reduce concern of bias due to missing data;
however, attrition was greater in the control arms, with the
main cause being disease progression, potentially resulting
in bias. We do not consider missing data due to attrition
an issue in these analyses, because we explicitly compare
HRQoL in patients with and without progression at each
assessment time (ANCOVA analysis), as well as assessing
change in HRQoL due to progression within patients (lon-
gitudinal model); therefore, the effect of attrition should
only be to reduce sample size at each assessment.
Furthermore, both studies extensively evaluated the
impact of missing data through sensitivity analyses and
found that differences in HRQoL questionnaire comple-
tion were unlikely to bias the ﬁndings of either study.
A limitation associated with all statistical methods that
estimate the effect of progression is that the comparison
is non-randomised (as in an observational study) leading
to potential bias. This potential bias was limited in the
ANCOVA analysis by using covariate adjustment, while
within patient comparisons in the longitudinal model
avoided bias as long as the piecewise linear model is
correct.
For ANCOVA as well as longitudinal analyses, data from
active and control treatment arms were pooled, which
assumes that the effect of progression on HRQoL is inde-
pendent of treatment. While this may be a potential
source of bias, the ANCOVA model included a term for
treatment as a covariate, and estimates of treatment-
speciﬁc effects of progression from mixed-effects longitu-
dinal models did not suggest that this was the case. It
should be considered that these ﬁndings are speciﬁc to
the type of patients with NSCLC enrolled in LUX-Lung 1
and LUX-Lung 3 and may not generalise to other patient
types. Finally, adverse events associated with afatinib treat-
ment have the potential to impact on speciﬁc HRQoL
items11 13 and thus have a confounding effect on the
results reported here. However, there were few grade 3/4
toxicities, which were confounded with assessments of
progression and when these effects were included in lon-
gitudinal models the effects of progression on HRQoL
were only slightly reduced (data not shown). Additionally,
the HRQoL measures used in these analyses (EORTC
Global Health/QoL, EQ-5D UK Utility and EQ VAS)
measure global health and thus would likely reﬂect the
effects of drug toxicity. Taking these points into consider-
ation, we do not believe drug toxicity is an important con-
founding factor in our analyses.
The demonstration of a relationship between PFS and
HRQoL in patients with lung cancer has important
implications for healthcare policy decision-making,
among others, in patients with NSCLC. It supports the
use of HRQoL measures in addition to traditional clin-
ical outcome measures such as PFS when making deci-
sions related to patient care, and the use of PFS as proof
of clinical efﬁcacy attributable to new treatments. This is
particularly relevant for new treatments that serve as
add-ons to existing chemotherapy regimens, when it is
often difﬁcult to show a HRQoL beneﬁt compared with
chemotherapy alone, or where OS beneﬁts are not
shown. This analysis validates the clinical meaningfulness
of PFS as a clinical trial end point.
CONCLUSION
The association between PFS and HRQoL reported here
supports the use of PFS as a primary endpoint in clinical
trials in patients with NSCLC, as it conﬁrms the value of
PFS as a patient-relevant endpoint associated with tan-
gible improvements in HRQoL.
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